FibroGen Stock Rises with HC Wainwright & Co. Price Target Increase to $43.00

FibroGen (FGEN) received a positive analyst update from HC Wainwright & Co., raising the price target from $10 to $43, a 330% increase. The company maintains a "Buy" rating, suggesting confidence in its future performance. FibroGen is a biotechnology company focused on developing novel therapeutics for serious cancer biology and anemia. The average analyst target price is $250, with an upside of 2,986% from the current price.

FibroGen Inc. (FGEN), a biotechnology company based in San Francisco, is set to report its quarterly results on August 11, 2025, for the period ending June 30, 2025. According to analyst estimates, the company is expected to show a significant decline in revenue, with a 94.8% decrease to $2.63 million from $50.64 million a year ago [1]. This fall in revenue is accompanied by a projected loss of $2.31 per share, based on the mean estimate from 2 analysts.

Despite the financial challenges, FibroGen has attracted a positive update from HC Wainwright analyst Patrick Trucchio. Trucchio raised the price target on FibroGen to $43 from $10, while maintaining a "Buy" rating. This upgrade underscores the analyst's bullish outlook on the company's prospects, particularly its pipeline of biopharmaceutical products [2]. The upgrade comes amidst a strong performance in the company's pipeline, which includes promising candidates for the treatment of fibrotic diseases.

FibroGen's lead candidate, FIB-101, has demonstrated promising results in Phase 2b trials, showing significant reductions in fibrosis markers. This positive data has bolstered confidence in the drug's efficacy and attracted the attention of other analysts. Canaccord Genuity raised its price target to $12, maintaining a "Buy" rating, while Aegis Capital reiterated its "Buy" rating with an $8 price target. Oppenheimer initiated coverage of FibroGen with an "Outperform" rating and a $14 price target [2].

The company is also advancing its drug, roxadustat, for treating anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell transfusion burden. FibroGen has reached an agreement with the FDA on key design elements for a pivotal Phase 3 clinical trial of roxadustat. The company plans to file the Phase 3 protocol in the fourth quarter of 2025, following positive feedback from a Type C meeting with the FDA [3].

However, FibroGen faces significant financial challenges. The company is quickly burning through cash with a debt burden of $91.2 million, which could impact its trial funding capabilities. Additionally, FibroGen's revenue has been declining, with a 80.6% drop in the last twelve months. The company has also made strategic divestment plans and is seeing promising developments in its product pipeline [3].

In conclusion, while FibroGen faces financial challenges, the positive analyst updates and promising pipeline developments suggest a positive outlook on the company's future prospects. The average analyst target price is $250, with an upside of 2,986% from the current price. FibroGen is well-positioned to make a significant impact in the biopharmaceutical industry.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U03OF:0-fibrogen-inc-expected-to-post-a-loss-of-2-31-a-share-earnings-preview/
[2] https://www.ainvest.com/news/fibrogen-hc-wainwright-raises-pt-43-10-maintains-buy-rating-2508/
[3] https://ca.investing.com/news/company-news/fibrogen-advances-roxadustat-for-anemia-in-myelodysplastic-syndromes-93CH-4142877